RESULTS
We performed immunohistochemistry with a C-terminusdirected antibody (see Appendix S1
1 ) to detect fl-NK1R expression in combination with CD3 for T cells and mastcell tryptase for mast cells. In normal human skin (NHS), surgically-induced scars (SIS), and in skin from 17 MF subjects (see Table SI 1 ), fl-NK1R was detected in upper spinous and granular cell layer keratinocytes, endothelial cells, and mast cells in accordance with previous studies ( [9] and see Appendix S1 1 , Fig. S1 1 and data not shown). In NHS, SIS, and in all MF subjects, epidermal or papillary dermal CD3
+ T lymphocytes lacked fl-NK1R ( ), randomly selected from the ELISA samples (Table SII 1 ). Circulating versus organ-specific T cells can differ in their synthesis and cell surface expression of proteins, and NK1R-expression has been reported in circulating T lymphocytes (10, 11) .
Given the presence of NK1R-expressing circulating T cells, we measured systemic SP levels in MF subjects whose demographics are presented in Table SII 1 . These samples were divided into early stage (stages Ia, Ib) and later stages (IIa-III). Compared to healthy controls (median, 25-75%: 194, 102.5-212.8 pg/ml), early (499, 267.9-574 pg/ml; p = 0.0106) and later-stage MF groups (541.7, 395.1-582.7 pg/ml; p = 0.0032) showed a significant increase in serum SP levels ( Fig. 1) . Expansion or proliferation of SP nerves in the papillary dermis did not account for the elevated systemic SP in MF subjects. SP(+) nerves are a minority of the total percent of PGP9.5+ intra-epidermal and papillary dermal nerves in MF subjects (median; 25-75%: 4.8%, 1.7-6.6%), similar to NHS (8.1%, 4.4-12.8%) (2) . SP-expressing nerves were located predominantly in the papillary dermis and rarely entered the epidermis in MF subjects (0%, 0-2.2% of PGP9.5+ intra-epidermal nerves) (Fig. 1) . SP expression was not detectable in CD3 + T cells or in mast cells in NHS or MFS ((2), Fig. 1 and Fig. S1 1 ).
DISCUSSION
We postulated that putative SP/NK1R signaling in migration, proliferation, and/or pruritus generation in MF would involve SP directly activating NK1R on malignant T cells (3, 5, 6) . Fl-NK1R was not detected in T cells in normal skin or MF skin lesions, including in 5 MF skin samples with known and active pruritus of the specific lesion biopsied at the time of biopsy. Our findings are potentially limited by the inability of the C-terminus antibody to detect the shorter NK1R isoform missing the last 96 amino acids of the C-terminus (7).
Given the absence of a functioning N-terminal antibody (see Appendix S1 1 ), we cannot exclude expression of truncated NK1R in MF subjects. Nevertheless, we found concordance between the expression pattern we obtained and that reported using labeled SP (9) . SP/NK1R signaling in MF skin lesions may play a biological role independent of fl-NK1R in skin T cells. The skin remains an important site for generation of pruritogens in MF, and SP may contribute through fl-NK1R-expressing keratinocytes or mast cells, or through malignant T cells using an NK1R-independent mechanism (12) .
The biological significance of the elevated systemic SP levels in MF is still unknown. In MF subjects, elevated SP levels occurred in the absence of a proliferation of SP-expressing papillary dermal nerves. Elevated SP levels correlated with itch intensity in atopic dermatitis (13) . In MF, both the degree of pruritus (1) and systemic SP levels increased with disease stage. Our study is limited by the absence of prospective quantitation of pruritus severity to correlate with serum SP measurements. Nevertheless, our data provide biologic rationale for a future such investigation to assess the contribution of systemic SP to MF itch.
In conclusion, elevated systemic SP levels may contribute to the pathophysiology of MF using fl-NK1R-expressing skin cells, central nervous system cells (7) , and now circulating lymphocytes. This complex distribution of NK1R expression highlights the need for both in vitro and prospective in vivo studies to ascertain further the contribution of SP and NK1R signaling to MF pathogenesis and pruritus. 
